Small impact of mild and moderate renal impairment on the pharmacokinetics of inhaled NVA237 Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
The influence of β2 adrenoceptor polymorphisms on the response to formoterol, montelukast or higher dose budesonide in patients with uncontrolled asthma despite low dose budesonide Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Lack of tolerance to the bronchoprotective effect with intermittent administration of salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 710s Year: 2006
Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with asthma Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Association of β2 -adrenoceptor genotypes with bronchodilatory effect of tiotropium in COPD Source: Annual Congress 2008 - Recent advances in the pathogenesis and treatment of asthma and COPD Year: 2008
Additive effects of montelukast in salmeterol treated moderate persistent asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 385s Year: 2002
The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD Source: Eur Respir J 2006; 28: Suppl. 50, 212s Year: 2006
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
The effect of long-term treatment with erdosteine on moderate or severe COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 292s Year: 2005
The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006
Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma Source: Eur Respir J 2001; 17: 374-379 Year: 2001
24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008
Therapeutic effect of low dose roxithromycin in chronic stable mild-to-moderate asthma Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Single therapeutic and supratherapeutic doses of indacaterol have little effect on systemic safety variables in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2007; 30: Suppl. 51, 357s Year: 2007
Bronchoprotective tolerance with indacaterol is not modified by concomitant tiotropium in persistent asthma Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017
Effects of low dose inhaled theophylline (ADC4022) co-administered with budesonide on inflammatory markers, lung function, and quality of life in COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Low dose inhaled budesonide with and without formoterol in steroid free patients with mild persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001